Outlook Therapeutics sets LYTENAVA US wholesale acquisition cost at $485/vial

Outlook Therapeutics, Inc.

On Sep 16, 2026, Outlook Therapeutics established LYTENAVA WAC at $485 per vial in the US.
Pricing applies to LYTENAVA, the company's ophthalmic product; no patient volumes or revenue disclosed.
WAC is the base wholesale list price; may affect reimbursement and distribution economics.
No guidance, clinical data, or launch-date details included in the filing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.